Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatino, D. E. Articles by Bodine, D. M. Search for Related Content PubMed PubMed Citation Articles by Sabatino, D. E. Articles by Bodine, D. M.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, November 1998, p. 6634-6640, Vol. 18, No. 11
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Substitution of the Human -Spectrin Promoter for the Human ^A-Globin Promoter Prevents Silencing of a Linked Human -Globin Gene in Transgenic Mice

Denise E. Sabatino,¹ Amanda P. Cline,¹ Patrick G. Gallagher,² Lisa J. Garrett,¹ George Stamatoyannopoulos,³ Bernard G. Forget,² and David M. Bodine^1,*

Hematopoiesis Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland¹; Yale University, New Haven, Connecticut²; and University of Washington, Seattle, Washington³

Received 18 May 1998/Returned for modification 6 July 1998/Accepted 23 July 1998

	ABSTRACT

Top Abstract Introduction Materials & Methods Results Discussion References

During development, changes occur in both the sites of erythropoiesis and the globin genes expressed at each developmental stage. Previous work has shown that high-level expression of human -like globin genes in transgenic mice requires the presence of the locus control region (LCR). Models of hemoglobin switching propose that the LCR and/or stage-specific elements interact with globin gene sequences to activate specific genes in erythroid cells. To test these models, we generated transgenic mice which contain the human ^A-globin gene linked to a 576-bp fragment containing the human -spectrin promoter. In these mice, the -spectrin ^A-globin (sp/^A) transgene was expressed at high levels in erythroid cells throughout development. Transgenic mice containing a 40-kb cosmid construct with the micro-LCR, sp/^A-, -, -, and -globin genes showed no developmental switching and expressed both human - and -globin mRNAs in erythroid cells throughout development. Mice containing control cosmids with the ^A-globin gene promoter showed developmental switching and expressed ^A-globin mRNA in yolk sac and fetal liver erythroid cells and -globin mRNA in fetal liver and adult erythroid cells. Our results suggest that replacement of the -globin promoter with the -spectrin promoter allows the expression of the -globin gene. We conclude that the -globin promoter is necessary and sufficient to suppress the expression of the -globin gene in yolk sac erythroid cells.

	INTRODUCTION

Top Abstract Introduction Materials & Methods Results Discussion References

Hemoglobin switching describes the changes that occur in the sites of erythropoiesis during development as well as the changes in the globin genes that are expressed (51). The human -like globin genes (5'^GA3') are located in an ~75-kb region on the short arm of chromosome 11 and are arranged 5' to 3' in the order in which they are expressed during development (9, 58). The earliest human erythroid cells express -globin and are derived from the embryonic yolk sac. At 16 weeks of gestation, the fetal liver is the site of erythropoiesis. Fetal liver-derived erythroid cells express the duplicated -globin genes, while the -globin gene is silenced (45). By birth, the major site of erythropoiesis is the bone marrow, which expresses the - and -globin genes only (for reviews, see references 9, 23, 31, 51, and 58).

The locus control region (LCR), a group of DNase I-hypersensitive sites located upstream of the globin cluster, is the most important cis-regulatory element for the -like globin cluster (14, 19). Many studies have shown that the LCR is essential for high-level expression of globin genes in transgenic mice (15, 19, 47). In the absence of the LCR, individual human -like globin genes are expressed in transgenic mice at low levels but in a developmentally appropriate manner (7, 26, 29, 52, 53).

The effects of the LCR on the developmental stage-specific expression of the human -like globin genes are complex. In transgenic mice with the LCR and a single human - or -globin gene, no developmental stage-specific expression has been observed (23, 31). The globin genes are expressed in yolk sac, fetal liver, and adult erythroid cells. However, when the LCR was linked to both a - and a -globin gene, the developmental changes in gene expression were restored; the -globin genes were expressed in yolk sac- and fetal liver-derived erythroid cells, and the -globin genes were expressed in fetal liver and adult erythroid cells (4, 12). Other studies made use of marked -globin genes whose mRNAs could be distinguished from those of unmarked -globin genes. Marked -globin genes were inserted at different positions within a -globin locus cosmid. These studies showed that both the position of the marked -globin gene and the distance between the LCR and the genes in the cosmid construct determined the levels of both the marked and unmarked -globin mRNAs (10, 39).

These and other studies of hemoglobin switching have suggested several models for the developmental regulation of the -like globin genes which are not mutually exclusive. One model suggests that the gene order and distance of a gene from the LCR (polarity) determine the correct developmental expression pattern (20, 39). A second model proposes that the LCR serves only as an enhancer element, allowing high-level expression of the globin genes which are activated by developmental stage-specific elements (31). The competition model proposes that erythroid cells of each developmental stage contain stage-specific elements which compete for and stabilize interactions between globin genes and the LCR (8, 23).

All of these models suggest that elements near or within the individual globin genes are required for developmental activation and/or suppression of the -like globin locus. Physical evidence for interactions between the LCR and individual globin genes has been shown by in situ hybridization analysis of erythroid cells from transgenic mice with a complete -globin locus. Analysis of individual nuclei labeled with LCR, -globin, and -globin probes have shown that the LCR interacts with only "one gene at a time" (56).

Other studies have shown that transgenic mice containing an LCR, a -globin gene with a promoter deletion, and the -globin gene do not express the -globin gene at any stage of development, while the -globin gene is expressed throughout development (3). Similarly, transient transfection studies of K562 cells have demonstrated that deletion of the proximal -globin promoter allows expression from a downstream -globin promoter (24, 25). Both groups concluded that the -globin promoter sequences were responsible for the silencing of the downstream -globin gene, but they could not exclude the possibility that -globin gene expression prevented -globin gene expression in embryonic erythroid cells.

One prediction of the competition model for hemoglobin switching is that a heterologous promoter attached to a -globin gene would not compete for stage-specific elements or the LCR and would therefore permit the expression of a downstream -globin gene in embryonic erythroid cells. To test this hypothesis, we fused a 576-bp fragment of the human -spectrin promoter characterized by Gallagher et al. (18) to a human -globin gene and generated transgenic mice containing the -spectrin/^A-globin gene. We chose the promoter from the -spectrin gene because -spectrin is expressed at relatively high levels in erythroid tissues and does not exhibit changes in expression during development (44, 57).

Analysis of transgenic mice containing only -spectrin/^A-globin genes demonstrated that the human -spectrin promoter directed high levels of -globin mRNA in the absence of the LCR at all stages of development. In transgenic mice in which the human -spectrin promoter was substituted for the human ^A-globin promoter in a cosmid construct containing a micro-LCR (µLCR) and ^A-, -, -, and -globin genes, both the -spectrin/^A-globin and -globin genes are expressed throughout development. We conclude from these data that sequences within the -globin promoter, and not -globin transcription or intragenic sequences, are necessary and sufficient to silence the downstream -globin gene.

(This work was performed by Denise E. Sabatino in partial fulfillment of the doctoral degree requirements in the Graduate Genetics Program of the Columbian School of Arts and Sciences at George Washington University.)

	MATERIALS AND METHODS

Top Abstract Introduction Materials & Methods Results Discussion References

Plasmid and cosmid constructs. A 576-bp fragment containing the -spectrin promoter (sp) was excised from pGL2B (18) as a KpnI/HindIII fragment and cloned into the KpnI/HindIII sites of pSP72. The HindIII site in plasmid pSP72 sp was destroyed by digestion with HindIII, filling in the ends, and religation. A 1,909-bp BsaHI/HindIII fragment containing the coding region of the human ^A-globin gene was cloned into the ClaI/HindIII sites of pSP72. A 2,614-bp AatII/PvuII fragment from the sp plasmid was ligated to a 2,266-bp EcoRV/AatII fragment from the ^A-globin plasmid to create pSP72 sp/^A. The construct was confirmed by sequencing across the sp/^A exon 1 region. The 2,483-bp sp/^A gene was excised from this plasmid with EcoRV and HindIII for microinjection.

HS2 sp/^A was generated by a triple ligation using a 712-bp XhoI/HincII fragment containing hypersensitive site 2 (HS2) of the LCR (33, 50), a 2,483-bp EcoRV/HindIII fragment containing sp/^A, and the vector pBluescript II KS+ cut with XhoI and HindIII. The 3,182-bp HS2 sp/^A gene was excised from this plasmid with HindIII for microinjection.

The pBluescript II KS+ plasmid vector was modified by replacing the BstXI site in the polylinker with KpnI and Bsp120I sites to generate BS*. A 4,428-bp NotI/XhoI fragment of the µLCR^A cosmid (12) containing the µLCR and a portion of the ^A gene was cloned into the NotI/XhoI sites of BS* to generate µLCR ^A 5'. This plasmid was digested with NotI and BamHI (polylinker) to generate the 2,972-bp fragment 1 of a four-part ligation. Fragment 2 was a 2,552-bp NotI/HindIII fragment containing the µLCR gene sequences from µLCR ^A5'. Fragment 3 was a 964-bp HindIII/StuI fragment of µLCR ^A 5' containing the sequences from 1345 to 381 upstream of the ^A promoter. The KpnI site in the 5' polylinker of pSP72 sp/^A was destroyed by KpnI digestion, filling in the ends, and religation. Fragment 4 was a 1,042-bp EcoRV/BamHI fragment containing sp/^A gene sequences from this plasmid. The product of this ligation was designated µLCR sp/^A 5'. This plasmid was partially digested with Bsp120I and completely digested with HindIII to generate the 2,580-bp fragment 1 of a three-part ligation containing the µLCR. Plasmid µLCR sp/^A 5' was digested partially with XhoI and completely with HindIII to generate the 2,059-bp fragment 2 containing sp/^A and upstream sequences. The third fragment was a 35.2-kb NotI/XhoI fragment of the µLCR^A cosmid (12). The resulting ligation generated the µLCRsp^A cosmid. The 40-kb µLCRsp^A fragment was excised from this cosmid by digestion with KpnI for microinjection. The control µLCR^A fragment was excised from the µLCR^A cosmid by digestion with NotI and KpnI for microinjection as described previously (12).

Generation of transgenic mice. Transgenic mice were generated as described by Hogan et al. (21). Fertilized eggs were collected from superovulating FVB/N female mice approximately 9 h after mating to CB6 F₁ male mice. Fragments for microinjection were separated on agarose gels and concentrated by using a DNA Geneclean isolation system according to the manufacturer's instructions. The fragments were diluted to a concentration of 1 µg/ml in 7.5 mM Tris-HCl-0.25 mM EDTA (pH 7.5), and 1 to 3 pl was injected into the male pronuclei of fertilized eggs. The injected eggs were transferred to pseudopregnant CB6 F₁ foster mothers. Founder animals were identified by Southern blotting (30) of DNA extracted from tail biopsies. Southern blots were probed with human -spectrin and/or human -globin probes. Copy number was determined by comparing transgenic mouse DNA to K562 DNA on a Southern blot and analysis using a Molecular Dynamics PhosphorImager. Founder animals were crossed to FVB/N mice for propagation and developmental studies.

Cellulose acetate electrophoresis. Blood samples were collected from 10.5-day embryos, 13.5-day embryos, and adult mice. Samples were lysed in cystamine as described by Whitney (55). Samples were run at 300 V for 20 min in a Titan electrophoresis chamber (Helena Laboratories), stained with Ponceau S (in 5% trichloroacetic acid) for 10 min, and destained in 7% acetic acid for 10 min (twice). The gels were fixed in methanol for 5 min (twice), cleared in a solution of 15 ml of glacial acetic acid, 35 ml of methanol, and 2 ml of Clear Aid for 7.5 min, and dried at 50 to 60°C for 15 min. The globin chain composing each hemoglobin tetramer was confirmed by acid-urea gel electrophoresis (1) of hemoglobins separated by cellulose acetate electrophoresis.

RNase protection assays. Total cellular RNA was extracted from 10.5-day embryo blood cells, 13.5-day fetal livers, and adult reticulocytes, using TRIZOL reagent (Gibco BRL, Life Technologies, Inc., Grand Island, N.Y.). Linear DNA templates for the RNase protection assay were prepared by EcoRI (sp/^A), HindIII (mouse ), and HindIII (human ) digestion of cesium chloride-purified plasmid preparations. The templates were purified by agarose gel electrophoresis and purified by using a Geneclean II kit (Bio 101, Inc., Vista, Calif.). ³²P-labeled RNA probes were transcribed by using a MAXIscript in vitro transcription kit (Ambion, Inc., Austin, Tex.). Hybridization of the probe and the RNA (1 µg) was carried out overnight according to the standard procedure for the RPA II RNase protection assay kit (Ambion). RNase digestion was performed with an RNase A-RNase T₁ mixture in RNase digestion buffer (Ambion), and the protected fragments were separated on an 8% nondenaturing polyacrylamide gel (SEQUAGEL-8; National Diagnostics, Atlanta, Ga.).

Immunofluorescence analysis. Fetal liver cells from transgenic mice and control littermates were stained with two monoclonal antibodies. One antibody, directed against human -globin, was directly conjugated to fluorescein isothiocyanate (FITC); the second monoclonal antibody, against human -globin, was directly conjugated to rhodamine. The same field of cells was photographed under different exposure conditions: with an FITC filter (for detection of -globin), with a rhodamine filter (for detection of -globin), and with first an FITC filter and then a rhodamine filter for a double exposure.

	RESULTS

Top Abstract Introduction Materials & Methods Results Discussion References

Transgenic mice with human -globin single-gene constructs. We created two single-gene constructs containing the -spectrin promoter fragment linked to the human ^A-globin gene, sp/^A and HS2 sp/^A (6, 15, 27, 33, 42, 50, 54) (Fig. 1; see Materials and Methods). Three transgenic mouse lines and two 13.5-day fetal livers containing sp/^A were analyzed. RNase protection demonstrated that two of three sp/^A transgenic lines and one of two fetal livers expressed the sp/^A transgene in erythroid cells. No sp/^A mRNA was detected in erythroid cells of the third transgenic line and the other fetal liver. Analysis of RNA extracted from a variety of organs and tissues of adult sp/^A transgenic mice revealed high levels of sp/^A mRNA in reticulocytes, bone marrow, and spleen and lower levels in thymus and other tissues (Fig. 2) (18). Much of the globin mRNA in nonerythroid cells can be attributed to the high reticulocyte counts (~15%) associated with a mild thalassemia caused by the excess of -like globin chains in these and all other transgenic mouse lines described in this study (18).

View larger version (17K): [in this window] [in a new window]   FIG. 1.   -Spectrin/-globin single-gene constructs used to generate transgenic mice. The -spectrin promoter fragment (576 bp) is fused to the A coding sequence at position 3 (A). A 712-bp fragment containing HS2 of the LCR is linked to the -spectrin/-globin gene (B). Transgenic mice were identified by Southern blot analysis using a 576-bp -spectrin promoter probe.

View larger version (35K): [in this window] [in a new window]   FIG. 2.   RNase protection analysis of sp/A mRNA expression in transgenic mice. (A) RNase protection of 10 µg of K562 RNA and 1 µg of adult reticulocyte mRNA from strain sp/A A. 32P-labeled 1,493-bp RNA containing sp/A gene sequences from exon 2, intron 1, and the sp/A exon 1 fusion region was used as a probe. The positions of 32P-labeled, protected RNA fragments corresponding to A-globin exon 2, sp/A exon 1, and A-globin exon 1 are indicated. (B) RNase protection of 1 µg of bone marrow (BM) and spleen RNA and 10 µg of thymus RNA from strain sp/A A. Labeled RNA fragments corresponding to the sp/A (exon 2 shown), mouse -globin (exon 2), and mouse actin (control) mRNAs were used as probes.

The number of transgenes in each line was estimated by Southern blot analysis to be between three and six copies per expressing animal (Table 1). The level of sp/^A mRNA was compared to the mRNA output of the four mouse -globin genes. After correction for copy number, the mean sp/^A globin gene mRNA level in adult reticulocytes was approximately 32% of the level of the -globin mRNA (Table 1).

View this table: [in this window] [in a new window]   TABLE 1.   Expression of sp/A mRNA in transgenic mouse lines

Six transgenic lines and one 13.5-day fetal liver containing HS2 sp/^A were analyzed. Expression of sp/^A was detected in erythroid cells of all six lines and the fetal liver. Southern blot analysis revealed a copy number of 0.5 to 3 copies per animal. Two animals with less than one copy per cell did not transmit transgenes to F₁ progeny and were determined to be mosaic for the transgene. After correction for copy number, the mean level of sp/^A mRNA in adult reticulocytes was 47% of the level of -globin mRNA (Table 1). This difference was not statistically different from the levels observed in sp/^A transgenic mice.

RNA was extracted from 10.5-day-postcoitum (dpc) yolk sac derived peripheral blood cells, 13.5-dpc fetal livers, and adult reticulocytes for RNase protection analysis of sp/^A mRNA levels during development. In all transgenic lines expressing either sp/^A or HS2 sp/^A, the -globin gene was expressed at all developmental stages at levels ranging from 4 to 37% of the levels of mouse -globin expression in the same cells (Fig. 3; Table 1).

View larger version (45K): [in this window] [in a new window]   FIG. 3.   RNase protection of 1 µg of 10.5-day embryonic blood, 13.5-day fetal liver, and adult reticulocyte RNAs from strains sp/A A and C (A) and from strains HS2 sp/A B and C (B). Labeled RNA fragments corresponding to the sp/A (exon 2 shown) and mouse -globin (exon 2) genes were used as probes.

Cellulose acetate electrophoresis was performed to confirm the presence of both -globin chains in 13.5-day fetal liver and adult erythrocytes. The fetal and adult erythrocytes of sp/^A and HS2 sp/^A transgenic mice contained endogenous mouse hemoglobins as well as an additional hemoglobin band composed of two mouse -globin chains and two human -globin chains (Fig. 4). These results were confirmed by acid-urea gel electrophoresis and high-pressure liquid chromatography (HPLC) analysis (data not shown).

View larger version (46K): [in this window] [in a new window]   FIG. 4.   Cellulose acetate electrophoresis of 14.5-day (A) and adult (B) peripheral blood lysates from strain sp/A A. Positions of the endogenous mouse hemoglobins and the mouse -2/human -2 hemoglobin tetramer are shown. +, blood lysate from transgenic animal; , blood lysate from littermate control.

Transgenic mice with cosmid gene constructs. A 37-kb µLCR^A cosmid construct (Fig. 5) containing a 4-kb µLCR linked to the ^A-, -, -, and -globin genes was modified by replacing 381 bp of the ^A-globin promoter with the 576-bp -spectrin promoter (Fig. 5). Three transgenic founder animals were generated with the resulting µLCRsp^A cosmid. High levels of sp/^A mRNA were detected in RNA from reticulocytes, bone marrow, and spleen, and no sp/^A mRNA was detected in RNA from thymus (Fig. 6). Southern blot analysis showed that these lines contained between 8 and 40 copies of the cosmid. One transgenic founder animal (strain C) did not transmit the transgene to F₁ progeny and was concluded to be mosaic for the transgene. Transgene expression in this line was studied only in the founder animal. Three additional transgenic lines containing the control µLCR^A cosmid construct were generated for comparison.

View larger version (9K): [in this window] [in a new window]   FIG. 5.   Control and sp/A cosmid constructs used to generate transgenic mice. The control µLCRA cosmid originally described by Enver et al. (12) (A) was modified to replace the A promoter region from 381 to 1 with a 576-bp fragment of the human -spectrin promoter (B). Transgenic mice were identified by Southern blot analysis using a 576-bp fragment containing the human -spectrin promoter region and a 960-bp fragment containing exon 2 of the human -globin gene as probes.

View larger version (38K): [in this window] [in a new window]   FIG. 6.   Analysis of sp/A mRNA expression in transgenic mice containing the µLCRA cosmid by RNase protection assay of 1 µg of bone marrow (BM) and spleen RNA and 10 µg of thymus RNA from strain µLCRspA A. Labeled RNA fragments corresponding to the sp/A (exon 2 shown), mouse -globin (exon 2), and mouse actin (control) genes were used as probes.

RNA was extracted from 10.5-dpc blood, 13.5-dpc fetal liver, and adult reticulocytes for RNase protection analysis of human - and -globin mRNA levels during development. As described previously (12), we detected -globin mRNA in yolk sac and fetal liver and -globin mRNA in fetal liver and adult erythroid cells of transgenic lines with the control µLCR^A cosmid (Fig. 7; Table 2). In contrast, both sp/^A mRNA and human -globin mRNA were detected at high levels in yolk sac, fetal liver, and adult erythroid cells of transgenic mice containing the µLCRsp^A cosmid (Fig. 7; Table 2).

View larger version (51K): [in this window] [in a new window]   FIG. 7.   RNase protection of 1 µg of 10.5-day embryonic blood, 13.5-day fetal liver, and adult reticulocyte RNA from control cosmid strain C (A) and from strain µLCRspA A (B). Labeled RNA fragments corresponding to the sp/A (exon 2 shown), human -globin (exon 3), and mouse -globin (exon 2) genes were used as probes.

View this table: [in this window] [in a new window]   TABLE 2.   Expression of sp/A mRNA in µLCRspA and µLCRA transgenic mouse lines

Cellulose acetate electrophoresis was performed to confirm the presence of both - and -globin chains in 13.5-day fetal liver and adult erythrocytes. Fetal erythrocytes from transgenic mice with either the control µLCR^A cosmid or the µLCRsp^A cosmid contained endogenous mouse hemoglobins as well as two additional hemoglobin bands consisting of two mouse -globin and two human -globin chains and two mouse -globin and two human -globin chains (Fig. 8). Adult peripheral blood of control µLCR^A cosmid transgenic mice contained only the endogenous mouse hemoglobins and the mouse -2/human -2 band. In contrast, adult erythrocytes of µLCRsp^A transgenic mice contained the endogenous mouse hemoglobins and both the mouse -2/human -2 and mouse -2/human -2 bands (Fig. 8). These results were confirmed by HPLC analysis (data not shown).

View larger version (34K): [in this window] [in a new window]   FIG. 8.   Cellulose acetate electrophoresis of 14.5-day (14.5d) and adult peripheral blood lysates from control µLCRA C (left) and µLCRspA A (right) transgenic mice. The positions of the endogenous mouse hemoglobins, the mouse -2/human -2 hemoglobin tetramer, and the mouse -2/human -2 hemoglobin tetramer are shown. +, blood lysate from transgenic animal; , blood lysate from littermate control.

Immunofluorescence analysis of 14.5-dpc fetal livers from µLCRsp^A embryos. Immunofluorescence analysis of human - and -globin gene expression was done on 14.5-dpc fetal livers from µLCRsp^A transgenic embryos and control µLCR^A cosmid-containing embryos. As previously described, fetal liver cells from control µLCR^A cosmid-containing mice expressed either human -globin or human -globin (12). Fetal liver cells from µLCRsp^A cosmid-containing mice all expressed both human -globin and human -globin (Fig. 9).

View larger version (84K): [in this window] [in a new window]   FIG. 9.   Immunofluorescence analysis of sp/A and human -globin chains in fetal liver cells from µLCRspA transgenic mice. The fetal liver cells were fixed and stained with conjugated monoclonal antibodies against human -globin (FITC) and human -globin (rhodamine). The identical field was photographed with an FITC filter (), a rhodamine filter (), and both filters (+).

	DISCUSSION

Top Abstract Introduction Materials & Methods Results Discussion References

Analysis of transgenic mice containing either cosmids or yeast artificial chromosomes (YACs) has shown that appropriate developmental regulation requires the presence of an active globin gene or genes upstream of the -globin gene (4, 11, 12, 16, 17, 28, 37, 40, 43). However, these studies have not identified the specific sequences involved. Analysis of deletion constructs in transgenic mice or cultured cells demonstrated that deletion of the -globin promoter allowed expression of the downstream -globin gene (3, 24). However, the same deletions which allow -globin gene expression abolished -globin gene expression. Our data support the competition model for hemoglobin switching, which posits that the individual globin genes compete for stage-specific elements to stabilize transcription of individual globin genes. By replacing the -globin promoter with the -spectrin promoter, the -globin gene is expressed at all stages of development in the presence of -globin gene expression. We conclude that the sequences between 381 and +1 of the -globin promoter, and not -globin transcription or intragenic sequences, are necessary and sufficient to silence the downstream -globin gene in the embryonic stage of development.

The observation that the -spectrin promoter is an enhancer-dependent and erythroid cell-specific promoter makes it an ideal promoter for the studies described here. Previous analyses of transgenic mice carrying phosphoglycerate kinase-Neo gene constructs inserted into either the mouse -globin locus (49) or the mouse (13, 22) and human (5, 38) LCRs had strikingly negative effects on globin gene expression. It is clear from these studies that the phosphoglycerate kinase gene promoter or Neo sequences are not neutral substitutions and that they may be strong competitors for stage-specific elements and/or the LCR (41).

Our data also support models in which specific sequences in the -globin promoter capture the LCR in the yolk sac erythroid cells and prevent -globin gene expression (2, 8, 24, 25). The testing of this model, and the importance of gene order and polarity, would require substitution of the -spectrin promoter for the ^A-globin promoter in a YAC construct, which would place two globin promoters upstream of the -spectrin promoter. If the LCR specifically interacts with these promoters, we hypothesize that expression of the -globin gene will be suppressed in yolk sac erythroid cells.

Our data are not consistent with some aspects of the models in which stage-specific elements alone are responsible for hemoglobin switching (31). These models posit that the presence of an enhancer-dependent -globin gene might be sufficient to suppress -globin expression in the yolk sac, in contrast to what we observed. The possibility that the -spectrin promoter does not compete with the -globin promoter for the same stage-specific factors which interact with the -globin promoter can be tested in the YAC experiments as well.

Since the sp/^A globin gene is expressed at relatively high levels in erythroid cells at all stages of development, sp/^A transgenic mice may be useful to test the effects of -globin on the amelioration of sickling in the sickle cell disease mouse model (35, 48). Previous in vitro studies have demonstrated that the amount of hemoglobin S (HbS) polymers decreases with increasing proportions of HbF, reaching a maximum inhibition of polymerization at 20% HbF (34). Other studies have found that as the HbF concentration increases, the severity of sickle cell disease decreases, with significantly less severe disease with >10% HbF (32, 36, 46). Generating sickle cell disease mice carrying the sp/^A gene would test whether the ^A-globin expressed from the -spectrin promoter is sufficient to reduce HbS polymerization in the mouse model.

	ACKNOWLEDGMENTS

We thank Qiliang Li for providing the µLCR^A cosmid, Thalia Papayannopoulou and Betty Nakamoto for immunofluoresence analysis, and Griffin Rodgers for HPLC analysis. We also thank Nancy Seidel for providing K562 RNA and Theresa Hernandez for assistance in maintaining the mouse colony.

	FOOTNOTES

^* Corresponding author. Mailing address: Hematopoiesis Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Building 49, Room 3A14 MSC 4442, Bethesda, MD 20892-4442. Phone: (301) 402-0902. Fax: (301) 402-4929. E-mail: tedyaz{at}nhgri.nih.gov.

	REFERENCES

Top Abstract Introduction Materials & Methods Results Discussion References

1.	Alter, B. P., S. C. Goff, G. D. Efremov, M. E. Graveley, and T. H. J. Huisman. 1980. Globin chain electrophoresis: a new approach to the determination of the G/A ratio in fetal haemoglobin and to studies of globin synthesis. Br. J. Haematol. 44:527-534[Medline].
2.	Amrolia, P. J., L. Ramamurthy, D. Saluja, N. Tanese, S. M. Jane, and J. M. Cunningham. 1997. The activation domain of the enhancer binding protein p45NF-E2 interacts with TAFII130 and mediates long-range activation of the - and -globin gene loci in an erythroid cell line. Proc. Natl. Acad. Sci. USA 94:10051-10056[Abstract/Free Full Text].
3.	Anderson, K. P., J. A. Lloyd, E. Ponce, S. C. Crable, J. C. Neumann, and J. B. Lingrel. 1993. Regulated expression of the human -globin gene in transgenic mice requires an upstream globin or nonglobin promoter. Mol. Biol. Cell 4:1077-1085[Abstract].
4.	Behringer, R. R., T. M. Ryan, R. D. Palmiter, R. L. Brinster, and T. M. Townes. 1990. Human  to -globin gene switching in transgenic mice. Genes Dev. 4:380-389[Abstract/Free Full Text].
5.	Bungert, J., U. Dave, K.-C. Lim, K. H. Lieuw, J. A. Shavit, Q. Liu, and J. D. Engel. 1995. Synergistic regulation of human -globin switching by locus control region elements HS3 and HS4. Genes Dev. 9:3083-3096[Abstract/Free Full Text].
6.	Caterina, J. J., T. M. Ryan, K. M. Pawlik, R. D. Palmiter, R. L. Brinster, R. R. Behringer, and T. M. Townes. 1991. Human -globin locus control region: analysis of the 5' DNase I hypersensitive site HS2 in transgenic mice. Proc. Natl. Acad. Sci. USA 88:1626-1630[Abstract/Free Full Text].
7.	Chada, K., J. Magram, and F. Costantini. 1986. An embryonic pattern of expression of a human fetal globin gene in transgenic mice. Nature 319:685-689[Medline].
8.	Choi, O., and J. Engel. 1988. Developmental regulation of -globin gene switching. Cell 55:17-26[Medline].
9.	Collins, F. S., and S. M. Weissman. 1984. The molecular genetics of human hemoglobin. Prog. Nucleic Acid Res. Mol. Biol. 31:315-462[Medline].
10.	Dillon, N., J. Strouboulis, and F. Grosveld. 1995. The regulation of human -globin gene expression: polarity of transcriptional competition in the human -globin locus, p. 23-28. In G. Stamatoyannopoulos (ed.), Molecular biology of hemoglobin switching. Intercept Ltd., Andover, England.
11.	Enver, T., A. J. Ebens, W. C. Forrester, and G. Stamatoyannopoulos. 1989. The human -globin locus activation region alters the developmental fate of a human fetal globin gene in transgenic mice. Proc. Natl. Acad. Sci. USA 86:7033-7037[Abstract/Free Full Text].
12.	Enver, T., N. Raich, A. J. Ebens, T. Papayannopoulou, F. Costantini, and G. Stamatoyannopoulos. 1990. Developmental regulation of human fetal-to-adult globin gene switching in transgenic mice. Nature 344:309-313[Medline].
13.	Fiering, S., E. Epner, K. Robinson, Y. Zhuang, A. Telling, M. Hu, D. I. K. Martin, T. Enver, T. J. Ley, and M. Groudine. 1995. Targeted deletion of 5'HS2 of the murine -globin LCR reveals that it is not essential for proper regulation of the -globin locus. Genes Dev. 9:2203-2213[Abstract/Free Full Text].
14.	Forrester, W. C., U. Novak, R. Gelinas, and M. Groudine. 1989. Molecular analysis of the human -globin locus activation region. Proc. Natl. Acad. Sci. USA 86:5439-5443[Abstract/Free Full Text].
15.	Fraser, P., J. Hurst, P. Collis, and F. Grosveld. 1990. DNase I hypersensitive sites 1, 2 and 3 of the human -globin dominant control region direct position-independent expression. Nucleic Acids Res. 18:3503-3508[Abstract/Free Full Text].
16.	Furukawa, T., P. A. Navas, B. M. Josephson, K. R. Peterson, T. Papayannopoulou, and G. Stamatoyannopoulos. 1995. Coexpression of , G and A globin mRNA in embryonic red blood cells from a single copy -YAC transgenic mouse. Blood Cells Mol. Dis. 21:168-178[Medline].
17.	Gaensler, K. M., M. Kitamura, and Y. W. Kan. 1993. Germ-line transmission and developmental regulation of a 150-kb yeast artificial chromosome containing the human -globin locus in transgenic mice. Proc. Natl. Acad. Sci. USA 90:11381-11385[Abstract/Free Full Text].
18.	Gallagher, P. G., D. E. Sabatino, M. Romana, A. P. Cline, L. J. Garrett, D. M. Bodine, and B. G. Forget. A human -spectrin gene promoter directs high level expression in erythroid, but not muscle or neural cells. Submitted for publication.
19.	Grosveld, F., G. B. van Assendelft, D. R. Greaves, and G. Kollias. 1987. Position-independent, high-level expression of the human -globin gene in transgenic mice. Cell 51:975-985[Medline].
20.	Hanscombe, O., D. Whyatt, P. Fraser, N. Yannoutsos, D. Greaves, N. Dillon, and F. Grosveld. 1991. Importance of globin gene order for correct developmental expression. Genes Dev. 5:1387-1394[Abstract/Free Full Text].
21.	Hogan, B., F. Costantini, and E. Lacy. 1986. Manipulating the mouse embryo. A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
22.	Hug, B. A., R. L. Wesselschmidt, S. Fiering, M. A. Bender, E. Epner, M. Groudine, and T. J. Ley. 1996. Analysis of mice containing a targeted deletion of the murine -globin locus control region 5' hypersensitive site 3. Mol. Cell. Biol. 16:2906-2912[Abstract/Free Full Text].
23.	Jane, S. M., and J. M. Cunningham. 1996. Molecular mechanisms of hemoglobin switching. Int. J. Biochem. Cell Biol. 28:1197-1209[Medline].
24.	Jane, S. M., P. A. Ney, E. F. Vanin, D. L. Gumucio, and A. W. Nienhuis. 1992. Identification of a stage selector element in the human gamma-globin gene promoter that fosters preferential interaction with the 5' HS2 enhancer when in competition with the beta-promoter. EMBO J. 11:2961-2969[Medline].
25.	Jane, S. M., A. W. Nienhuis, and J. M. Cunningham. 1995. Hemoglobin switching in man and chicken is mediated by a heteromeric complex between the ubiquitous transcription factor CP2 and a developmentally specific protein. EMBO J. 14:97-105[Medline]. (Erratum, 14:854.)
26.	Kollias, G., N. Wrighton, J. Hurst, and F. Grosveld. 1986. Regulated expression of human A-, - and hybrid -globin genes in transgenic mice: manipulation of developmental expression patterns. Cell 46:89-94[Medline].
27.	Liu, D., J. C. Chang, P. Moi, W. Jiu, Y. W. Kan, and P. T. Curtin. 1992. Dissection of the enhancer activity of -globin 5' DNase I-hypersensitive site 2 in transgenic mice. Proc. Natl. Acad. Sci. USA 89:3899-3903[Abstract/Free Full Text].
28.	Liu, Q., J. Bungert, and J. Engel. 1997. Mutation of gene-proximal regulatory elements disrupts human -, -, and -globin expression in yeast artificial chromosome transgenic mice. Proc. Natl. Acad. Sci. USA 94:169-174[Abstract/Free Full Text].
29.	Magram, J., K. Chada, and F. Costantini. 1985. Developmental regulation of a cloned adult -globin gene in transgenic mice. Nature 315:338-340[Medline].
30.	Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
31.	Martin, D. I., S. Fiering, and M. Groudine. 1996. Regulation of -globin gene expression: straightening out the locus. Curr. Opin. Genet. Dev. 6:488-495[Medline].
32.	Miller, B. A., M. Salameh, M. Ahmed, N. Olivieri, T. Huisman, S. Orkin, and D. Nathan. 1987. Analysis of high fetal hemoglobin production in sickle cell anemia patients from the eastern province of Saudi Arabia, p. 415-426. In G. Stamatoyannopoulos, and A. Nienhuis (ed.), Developmental control of globin gene expression. Alan R. Liss, Inc., New York, N.Y.
33.	Ney, P. A., B. P. Sorrentino, K. T. McDonagh, and A. W. Nienhuis. 1990. Tandem AP-1-binding sites within the human -globin dominant control region function as an inducible enhancer in erythroid cells. Genes Dev. 4:993-1006[Abstract/Free Full Text].
34.	Noguchi, C. T., G. P. Rodgers, G. Serjeant, and A. N. Schechter. 1988. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N. Engl. J. Med. 318:96-99[Medline].
35.	Paszty, C., C. M. Brion, E. Manci, H. E. Witkowska, M. E. Stevens, N. Mohandas, and E. M. Rubin. 1997. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278:876-878[Abstract/Free Full Text].
36.	Perrine, R. P., M. J. Brown, J. B. Clegg, D. J. Weatherall, and A. May. 1972. Benign sickle cell anaemia. Lancet ii:1163-1167.
37.	Peterson, K. R., C. H. Clegg, C. Huxley, B. M. Josephson, H. S. Haugen, T. Furukawa, and G. Stamatoyannopoulos. 1993. Transgenic mice containing a 248-kb yeast artificial chromosome carrying the human -globin locus display proper developmental control of human globin genes. Proc. Natl. Acad. Sci. USA 90:7593-7597[Abstract/Free Full Text].
38.	Peterson, K. R., C. H. Clegg, P. A. Navas, E. J. Norton, T. G. Kimbrough, and G. Stamatoyannopoulos. 1996. Effect of deletion of 5'HS3 or 5'HS2 of the human -globin locus control region on the developmental regulation of globin gene expression in -globin locus yeast artificial chromosome transgenic mice. Proc. Natl. Acad. Sci. USA 93:6605-6609[Abstract/Free Full Text].
39.	Peterson, K. R., and G. Stamatoyannopoulos. 1993. Role of gene order in developmental control of human - and -globin gene expression. Mol. Cell. Biol. 13:4836-4843[Abstract/Free Full Text].
40.	Peterson, K. R., Q. L. Li, C. H. Clegg, T. Furukawa, P. A. Navas, E. J. Norton, T. C. Kimbrough, and G. Stamatoyannopoulos. 1995. Use of yeast artificial chromosomes (YACs) in studies of mammalian development: production of -globin locus YAC mice carrying human globin developmental mutants. Proc. Natl. Acad. Sci. USA 92:5655-5659[Abstract/Free Full Text].
41.	Pham, C. T. N., D. M. MacIvor, B. A. Hug, J. W. Heusel, and T. J. Ley. 1996. Long range disruption of gene expression by a selectable marker cassette. Proc. Natl. Acad. Sci. USA 93:13090-13095[Abstract/Free Full Text].
42.	Philipsen, S., D. Talbot, P. Fraser, and F. Grosveld. 1990. The -globin dominant control region: hypersensitive site 2. EMBO J. 9:2159-2167[Medline].
43.	Porcu, S., M. Kitamura, E. Witkowska, Z. Zhang, A. Mutero, C. Lin, J. Chang, and K. M. Gaensler. 1997. The human -globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. Blood 90:4602-4609[Abstract/Free Full Text].
44.	Prchal, J. T., T. Papayannopoulou, and S. Yoon. 1990. Patterns of spectrin transcripts in erythroid and non-erythroid cells. J. Cell. Physiol. 144:287-294[Medline].
45.	Raich, N., T. Enver, B. Nakamoto, B. Josephson, T. Papayannopoulou, and G. Stamatoyannopoulos. 1990. Autonomous developmental control of human embryonic globin gene switching in transgenic mice. Science 250:1147-1149[Abstract/Free Full Text].
46.	Rucknagel, D. L., S. A. Sarniak, C. F. Whitten, and D. A. Odenheimer. 1987. Fetal hemoglobin concentration predicts disease severity in children with sickle cell anemia, p. 487-496. In G. Stamatoyannopoulos, and A. Nienhuis (ed.), Developmental control of globin gene expression. Alan R. Liss, Inc., New York, N.Y.
47.	Ryan, T. M., R. R. Behringer, N. C. Martin, T. M. Townes, R. D. Palmiter, and R. L. Brinster. 1989. A single erythroid-specific DNase I super-hypersensitive site activates high levels of human -globin gene expression in transgenic mice. Genes Dev. 3:314-323[Abstract/Free Full Text].
48.	Ryan, T. M., D. J. Ciavatta, and T. M. Townes. 1997. Knockout-transgenic mouse model of sickle cell disease. Science 278:873-875[Abstract/Free Full Text].
49.	Shehee, W. R., P. Oliver, and O. Smithies. 1993. Lethal thalassemia after insertional disruption of the mouse major adult beta-globin gene. Proc. Natl. Acad. Sci. USA 90:3177-3181[Abstract/Free Full Text].
50.	Sorrentino, B., P. Ney, D. Bodine, and A. W. Nienhuis. 1990. A 46 base pair enhancer sequence within the locus activation region is required for induced expression of the -globin gene during erythroid differentiation. Nucleic Acids Res. 18:2721-2731[Abstract/Free Full Text].
51.	Stamatoyannopoulos, G., and A. W. Nienhuis. 1993. Hemoglobin switching, p. 107-156. In G. Stamatoyannopoulos, A. W. Nienhuis, and H. Varmus (ed.), Molecular basis of blood diseases. Saunders, Philadelphia, Pa.
52.	Starck, J., R. Sarker, M. Romana, A. Bhargava, A. L. Scarpa, M. Tanaka, J. W. Chamberlain, S. M. Weissman, and B. G. Forget. 1994. Developmental regulation of human - and -globin genes in the absence of the locus control region. Blood 84:1656-1665[Abstract/Free Full Text].
53.	Townes, T. M., J. B. Lingrel, H. Y. Chen, R. L. Brinster, and R. D. Palmiter. 1985. Erythroid-specific expression of human -globin genes in transgenic mice. EMBO J. 4:1715-1723[Medline].
54.	Tuan, D., W. Solomon, I. London, and D. Lee. 1989. An erythroid-specific, developmental-stage-independent enhancer far upstream of the human `-like globin' genes. Proc. Natl. Acad. Sci. USA 86:2554-2558[Abstract/Free Full Text].
55.	Whitney, J. B., III. 1978. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine. Biochem. Genet. 16:667-672[Medline].
56.	Wijgerde, M., F. Grosveld, and P. Fraser. 1995. Transcription complex stability and chromatin dynamics in vivo. Nature 377:209-213[Medline].
57.	Winkelmann, J. C., and B. G. Forget. 1993. Erythroid and nonerythroid spectrins. Blood 81:3173-3185[Abstract/Free Full Text].
58.	Wood, W. G., J. B. Clegg, and D. J. Weatherall. 1977. Developmental biology of human hemoglobins. Prog. Hematol. 10:43-90[Medline].

---

Molecular and Cellular Biology, November 1998, p. 6634-6640, Vol. 18, No. 11
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Beauchemin, H., Trudel, M. (2009). Evidence for a Bigenic Chromatin Subdomain in Regulation of the Fetal-to-Adult Hemoglobin Switch. Mol. Cell. Biol. 29: 1635-1648 [Abstract] [Full Text]  
• Kanno, H., Utsugisawa, T., Aizawa, S., Koizumi, T., Aisaki, K.-i., Hamada, T., Ogura, H., Fujii, H. (2007). Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency. haematol 92: 731-737 [Abstract] [Full Text]  
• Yu, M., Han, H., Xiang, P., Li, Q., Stamatoyannopoulos, G. (2006). Autonomous Silencing as Well as Competition Controls {gamma}-Globin Gene Expression during Development. Mol. Cell. Biol. 26: 4775-4781 [Abstract] [Full Text]  
• Gallagher, P. G., Nilson, D. G., Wong, C., Weisbein, J. L., Garrett-Beal, L. J., Eber, S. W., Bodine, D. M. (2005). A dinucleotide deletion in the ankyrin promoter alters gene expression, transcription initiation and TFIID complex formation in hereditary spherocytosis. Hum Mol Genet 14: 2501-2509 [Abstract] [Full Text]  
• Calderwood, M. S., Gannoun-Zaki, L., Wellems, T. E., Deitsch, K. W. (2003). Plasmodium falciparum var Genes Are Regulated by Two Regions with Separate Promoters, One Upstream of the Coding Region and a Second within the Intron. J. Biol. Chem. 278: 34125-34132 [Abstract] [Full Text]  
• Frazar, T. F., Weisbein, J. L., Anderson, S. M., Cline, A. P., Garrett, L. J., Felsenfeld, G., Gallagher, P. G., Bodine, D. M. (2003). Variegated Expression from the Murine Band 3 (AE1) Promoter in Transgenic Mice Is Associated with mRNA Transcript Initiation at Upstream Start Sites and Can Be Suppressed by the Addition of the Chicken {beta}-Globin 5' HS4 Insulator Element. Mol. Cell. Biol. 23: 4753-4763 [Abstract] [Full Text]  
• Persons, D. A., Hargrove, P. W., Allay, E. R., Hanawa, H., Nienhuis, A. W. (2003). The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma -globin gene is influenced by chromosomal position effects and vector copy number. Blood 101: 2175-2183 [Abstract] [Full Text]  
• Boulanger, L., Sabatino, D. E., Wong, E. Y., Cline, A. P., Garrett, L. J., Garbarz, M., Dhermy, D., Bodine, D. M., Gallagher, P. G. (2002). Erythroid Expression of the Human alpha -Spectrin Gene Promoter Is Mediated by GATA-1- and NF-E2-binding Proteins. J. Biol. Chem. 277: 41563-41570 [Abstract] [Full Text]  
• Gallagher, P. G., Sabatino, D. E., Basseres, D. S., Nilson, D. M., Wong, C., Cline, A. P., Garrett, L. J., Bodine, D. M. (2001). Erythrocyte Ankyrin Promoter Mutations Associated with Recessive Hereditary Spherocytosis Cause Significant Abnormalities in Ankyrin Expression. J. Biol. Chem. 276: 41683-41689 [Abstract] [Full Text]  
• Sargent, T. G., Lloyd, J. A. (2001). The Human gamma -Globin TATA and CACCC Elements Have Key, Distinct Roles in Suppressing beta -Globin Gene Expression in Embryonic/Fetal Development. J. Biol. Chem. 276: 41817-41824 [Abstract] [Full Text]  
• Moreau-Gaudry, F., Xia, P., Jiang, G., Perelman, N. P., Bauer, G., Ellis, J., Surinya, K. H., Mavilio, F., Shen, C.-K., Malik, P. (2001). High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 98: 2664-2672 [Abstract] [Full Text]  
• Persons, D. A., Allay, E. R., Sabatino, D. E., Kelly, P., Bodine, D. M., Nienhuis, A. W. (2001). Functional requirements for phenotypic correction of murine {beta}-thalassemia: implications for human gene therapy. Blood 97: 3275-3282 [Abstract] [Full Text]  
• Sabatino, D. E., Seidel, N. E., Aviles-Mendoza, G. J., Cline, A. P., Anderson, S. M., Gallagher, P. G., Bodine, D. M. (2000). Long-term expression of gamma -globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma -globin gene fused to the ankyrin-1 promoter. Proc. Natl. Acad. Sci. USA 10.1073/pnas.230453097v1 [Abstract] [Full Text]  
• Zhou, W., Clouston, D. R., Wang, X., Cerruti, L., Cunningham, J. M., Jane, S. M. (2000). Induction of Human Fetal Globin Gene Expression by a Novel Erythroid Factor, NF-E4. Mol. Cell. Biol. 20: 7662-7672 [Abstract] [Full Text]  
• Ryan, T. M., Sun, C.-W., Ren, J., Townes, T. M. (2000). Human {gamma}-globin gene promoter element regulates human {beta}-globin gene developmental specificity. Nucleic Acids Res 28: 2736-2740 [Abstract] [Full Text]  
• Sargent, T. G., DuBois, C. C., Buller, A. M., Lloyd, J. A. (1999). The Roles of 5'-HS2, 5'-HS3, and the gamma -Globin TATA, CACCC, and Stage Selector Elements in Suppression of beta -Globin Expression in Early Development. J. Biol. Chem. 274: 11229-11236 [Abstract] [Full Text]  
• Gallagher, P. G., Sabatino, D. E., Romana, M., Cline, A. P., Garrett, L. J., Bodine, D. M., Forget, B. G. (1999). A Human beta -Spectrin Gene Promoter Directs High Level Expression in Erythroid but Not Muscle or Neural Cells. J. Biol. Chem. 274: 6062-6073 [Abstract] [Full Text]  
• Sabatino, D. E., Wong, C., Cline, A. P., Pyle, L., Garrett, L. J., Gallagher, P. G., Bodine, D. M. (2000). A Minimal Ankyrin Promoter Linked to a Human gamma -Globin Gene Demonstrates Erythroid Specific Copy Number Dependent Expression with Minimal Position or Enhancer Dependence in Transgenic Mice. J. Biol. Chem. 275: 28549-28554 [Abstract] [Full Text]  
• Sabatino, D. E., Seidel, N. E., Aviles-Mendoza, G. J., Cline, A. P., Anderson, S. M., Gallagher, P. G., Bodine, D. M. (2000). Long-term expression of gamma -globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma -globin gene fused to the ankyrin-1 promoter. Proc. Natl. Acad. Sci. USA 97: 13294-13299 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatino, D. E. Articles by Bodine, D. M. Search for Related Content PubMed PubMed Citation Articles by Sabatino, D. E. Articles by Bodine, D. M.